ArticleMolecular neurobiology2025
Localization and Pathological Implications of Lipopolysaccharide in the Brains of 5XFAD Mice.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics profiling reveals gut microbiome signatures associated with cognitive decline in Alzheimer's disease.iScience · 2026Article
- The role of the microbiome on immune homeostasis of the host nervous system.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's disease (AD) is an irreversible disease characterized by a complex pathophysiology. Recent evidence consistently identifies inflammation as one of the contributing factors, along with the pathological aggregation and accumulation of amyloid-β (Aβ) peptides and hyperphosphorylated tau protein. Inflammation is suggested to have specific causative agents, of which lipopolysaccharide (LPS) may be important in AD. Interestingly, elevated LPS levels are found in patients with AD, and these elevated levels cause cognitive dysfunction in AD patients. Moreover, LPS contributes to neuroinflammation and Aβ and tau pathology in AD. However, questions remain about LPS presence/distribution in AD brains and its relationship with AD pathology. This study investigated (1) the changes in LPS presence/distribution in wild-type (WT) and 5XFAD mice, (2) the pathological role of LPS on Aβ and tau aggregation, and (3) the effect of LPS on neuroinflammatory response in vitro and in vivo. LPS accumulations were significantly increased in the 5XFAD brains compared to WT brains. Particularly, LPS distribution is increasing in the 5XFAD brains in an AD progression-dependent manner. Furthermore, LPS significantly increased aggregation of Aβ and tau and deteriorated neuroinflammatory response in vitro and in vivo. Thus, our results suggest that LPS contributes to AD pathology and modulation of LPS levels could be an effective therapeutic strategy for AD.
Indexed as
Identifiers
40490661What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.